8.2 Drugs affecting the immune response

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

1010 library items in 8.2 Drugs affecting the immune response

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

8: Malignant disease and immunosuppression (remove) , 8.2 Drugs affecting the immune response (remove)

Sort by: Display summary:

Results 1 - 10 of 1010

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Updated national IV monograph on Natalizumab

Source: Medusa,
Date published: 16/05/2012

Category:

8.2.4 Other immunomodulating drugs | Drug Administration

NeLM Area:

News

Link- registration required
2.

FDA Drug Safety Communication: Revised recommendations for cardiac monitoring and use of fingolimod (Gilenya®)

Source: FDA,
Date published: 15/05/2012

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | Food &Drug Administration (FDA) | Multiple sclerosis

NeLM Area:

News

Link
3.

Outcome at 5 years following response to rituximab therapy in children and adults with ITP

Source: Blood,
Date published: 15/05/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Haematology

NeLM Area:

News

Link (abstract)
4.

Generic immunosuppression: deciphering the message our patients are receiving

Source: Annals of Pharmacotherapy,
Date published: 15/05/2012

Category:

8.2 Drugs affecting the immune response | Generic prescribing

NeLM Area:

Evidence > Medicines Management > References

Abstract link
5.

New national IV monograph on Ofatumumab

Source: Medusa,
Date published: 15/05/2012

Category:

8.2.3 Anti-lymphocyte monoclonal antibodies | Drug Administration

NeLM Area:

News

Link- registration required
6.

Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients

Source: Research in Social and Administrative Pharmacy,
Date published: 14/05/2012

Category:

8.2 Drugs affecting the immune response | Compliance | Transplantation

NeLM Area:

Evidence > Medicines Management > References

Abstract link (ScienceDirect)
7.

Single agent maintenance therapy for advanced stage non-small cell lung cancer: meta-analysis

Source: Lung Cancer,
Date published: 10/05/2012

Category:

8.1 Cytotoxic drugs | 8.2 Drugs affecting the immune response | Cancer: lung

NeLM Area:

News

Abstract
8.

Horizon scanning: US and EU regulatory authorities accept for review marketing applications for oral dimethyl fumarate (BG-12) for treatment of multiple sclerosis

Source: PharmaLive,
Date published: 10/05/2012

Category:

8.2.4 Other immunomodulating drugs | Food &Drug Administration (FDA) | Multiple sclerosis | New drugs

NeLM Area:

News

Link
9.

RCTs of continuous lenalidomide treatment for multiple myeloma

Source: New England Journal of Medicine (NEJM),
Date published: 10/05/2012

Category:

8.2.4 Other immunomodulating drugs | Multiple myeloma | Transplantation

NeLM Area:

News

Abstract (newly diagnosed)

Abstract (stem cell transplantation 1)

Abstract (stem cell transplantation 2)

Editorial- full text may be restricted to subscribers
10.

FDA Drug Safety Communication: Increased risk of second primary malignancies in patients taking lenalidomide for multiple myeloma

Source: FDA MedWatch,
Date published: 08/05/2012

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | Food &Drug Administration (FDA) | Multiple myeloma

NeLM Area:

News

Link

Results 1 - 10 of 1010

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next